FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose Finding in Phase 1A
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Bemarituzumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FIGHT
- Sponsors Five Prime Therapeutics
- 02 Aug 2018 Planned End Date changed from 30 Jun 2018 to 28 Feb 2019.
- 02 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 24 Jul 2018.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.